Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
layoffs
Biotech
nChroma halves headcount, halts trial of potential HBV ‘cure’
nChroma’s workforce is facing another round of layoffs, with the Boston biotech halving its headcount and halting its lead hepatitis asset.
James Waldron
Nov 19, 2026 9:08am
Cellectis will shed 70% of workforce as part of in vivo pivot
Nov 13, 2026 9:18am
Fierce Biotech Layoff Tracker 2026: Milestone, Cellectis & more
Nov 13, 2026 7:00am
Capricor, NextCure shed light on recent layoffs
Nov 11, 2026 4:48am
Coherus shrinks headcount 30% to narrow focus of cancer combo
Nov 10, 2026 3:52am
Agios shedding 100 R&D roles ahead of hoped-for SCD approval
Nov 5, 2026 8:40am